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Abstract
Breast and ovarian cancers are among the 10 leading cancer types in females with mortalities of 15% and 6%,
respectively. Despite tremendous efforts to conquer malignant diseases, the war on cancer declared by Richard
Nixon four decades ago seems to be lost. Approximately 21,800 women in the US will be diagnosed with ovarian
cancer in 2011. Therefore, its incidence is relatively low compared to breast cancer with 207.090 prognosed cases
in 2011. However, overall survival unmasks ovarian cancer as the most deadly gynecological neoplasia. Platinum-
based chemotherapy is emerging as an upcoming treatment modality especially in triple negative breast cancer.
However, in ovarian cancer Platinum-complexes for a long time are established as first line treatment. Emergence
of a resistant phenotype is a major hurdle in curative cancer therapy approaches and many scientists around the
world are focussing on this issue. This review covers new findings in this field during the past decade.
Introduction
Among solid gynaecological tumors, breast cancer is the
most often diagnosed tumour while ovarian cancer is the
most deadly gynaecological neoplasia. Cisplatin plays a
completely different but important role in the treatment
of both female cancer types. In ovarian cancer treatment,
Platinum-based chemotherapy plays a pivotal role as first
line chemotherapy option and is usually combined with
taxanes [1]. In breast cancer treatment, cisplatin yet only
is regarded a cytostatic reserve. According to current
guidelines, treatment of breast cancer normally is per-
formed as chemotherapy triplets. The most commonly
used cytostatics in the clinical management of the disease
are Anthracyclines, Cyclophosphamide, Fluorouracil, and
Taxanes, respectively. Prominent examples of che-
motherapy combinations in breast cancer treatment are:
➢ FEC: Fluorouracil, Epirubicin, Cyclophosphamide
➢ FAC: Fluorouracil, Doxorubicine (Adriamycine),
Cyclophosphamide
➢ TAC: Docetaxane, Doxorubicine, Cyclophosphamide
➢ EC - P (or EC - D): Epirubicine, Cyclophospha-
mide followed by either Paclitaxane or Docetaxane
➢ FEC-Doc: Fluorouracil, Epirubicine, Cyclopho-
sphamide followed by Docetaxane
➢ TC: Docetaxane, Cyclophosphamide
➢ Formerly often applied CMF treatment regime
(consisting of Cyclophosphamide, Methotrexate, and
Fluorouracil) is nowadays more or less completely
substituted by the above mentioned.
Thus, cisplatin at present does not play a pivotal role in
clinical breast cancer therapy. However, Platinum-based
chemotherapy could develop into a highly important new
treatment modality with respect to yet incurable triple
negative breast cancer (TNBC) [2]. Especially two TNBC
subgroups seem to be amenable to Platinum-based che-
motherapy: basal-like 1 and 2 (BL1, BL2). These two sub-
groups are identified by their Gene Expression Signature
(GES) [3]. BL1 and BL2 subgroups of TNBC are character-
ized by high expression levels of DNA-damage response
genes, which induce cell cycle arrest and apoptosis [2].
Interestingly, in vitro cell culture experiments unveiled
this phenomenon and can possibly serve to predict the in
vivo situation [2]. A different but also promising new idea
is the use of PARP1 inhibitors as chemosensitisers in com-
bination with Platinum-based chemotherapy. Preliminary
results from clinical trials are promising and justify
researchers hope for better clinical management of the
disease in the near future as outlined in detail throughout
this article.
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Cisplatin (Platinex
®), Carboplatin (Carboplat
®), and Oxa-
liplatin (Eloxatin
®) (Figure 1) are first-line anti-cancer
drugs in a broad variety of malignancies, for instance:
ovarian cancer, testicular cancer and non small cell lung
cancer. Cisplatin is inactive when orally administered
and, thus, the prodrug Cisplatin must be toxicated endo-
genously. The active principle formed inside the cell is
the electrophile aquo-complex. High extracellular chlor-
ide concentrations (~100 mM) prevent extracellular
formation of the active complex. Upon entering the cell,
in a low chloride environment (~2-30 mM), the aquo-
complex is formed. The active principle is preferentially
built as a shift in the reaction balance. The mechanism of
action of the aquated complex at the molecular level is
covalent cross-linking of DNA nitrogen nucleophils. The
Cisplatin bisaquo-complex prefers an electrophilic reac-
tion with N-7 nitrogen atoms of adenine and guanine. 1,2
or 1,3 intra-strand cross links are preferentially built (to
an extent of about 90%). Affected are genomic and mito-
chondrial DNA molecules [4].
Carboplatin mechanistically acts similar to Cisplatin.
However, a slower pharmacokinetic profile and a different
spectrum of side effects has been reported [5]. The
mechanism of action of Oxaliplatin substantially differs
from Cis- and Carboplatin, which might be explained by
the lipophilic cyclohexane residue. Cisplatin has a broad
range of side effects. Problematic are nephro- and ototoxi-
city, but therapy-limiting is its extraordinary high potential
to cause nausea and emesis. Thus, Cisplatin usually is admi-
nistered together with potent anti-emetogens such as 5-
HT3 antagonits (Ondansetrone, Granisetrone or else). Car-
boplatin has a diminished nephro- and ototoxicity, but can
cause bone marrow depression, while oxaliplatins most
characteristic side effect is dose-dependent neurotoxicity.
Apoptosis attendant on DNA damage
Cytotoxic anti-cancer drugs excert their effect through
the induction of apoptosis. The Greek derived word
apoptosis (aπόπτωsις) literally means autumnally fall-
ing leaves, describing a subject to be doomed. It is often
refered to as programmed cell death. However, other
mechanisms of programmed cell death have been identi-
fied recently, like autophagy, paraptosis, and mitotic cat-
astrophe [6]. To this end, apoptosis more accurately is
defined as cell death induced by caspases. Caspases are
synthesized as inactive precursor proteins (procaspases)
and activated upon proteolytic processing. They are
divided into two major grous: (i) proinflammatory cas-
pases (subtypes 1, 4, 5, 11, 12, 13, and 14) and (ii) proa-
poptotic caspases. Caspases triggering apoptosis are
further categorized into initiating caspases (subtypes 2,
8, 9, and 10) and effector caspases (subtypes 3, 6, and 7)
(reviewed in [7]).
Two apoptosis mediating pathways are divided, the
intrinsic and the extrinsic apoptotic signaling pathway,
with the latter induced by specific ligand-receptor inter-
action (for instance FasL - Fas interaction). The intrinsic
apoptotic signaling cascade triggeres cell death induced
by cytotoxic drugs. Accordingly, it is triggered among
others by DNA damage [8]. This pathway is balanced by
pro- and anti-apoptotic members of the Bcl-2 protein
family. The tumour-supressor protein p53 is a pivotal
point for the activation of the intrinsic apoptotic path-
way: p53 responds to diverse cellular stresses by arrest-
ing cell cycle progression through expression of p53
target genes such as the mitotic inhibitors p27 and p21.
After unrepairable DNA damage, p53 triggeres cell
death via the expression of apoptotic genes (puma,
noxa, etc.) and by inhibiting the expression of anti-
apoptotic genes [9].
Mechanisms of Cisplatin resistance
Cancer is one of the most deadly diseases world-wide with
projected 1.596.670 new cases in 2011 in the USA alone
[10]. Remarkable exceptions from this deadly rule are
germ cell tumors of the ovary and testicular cancer when
treated with cisplatin for which they show extraordinary
Figure 1 Structure formulas of platinum-complexes. Cisplatin, Carboplatin, and Oxaliplatin. Cis- and Carboplatin show high degree of cross-
resistance, while oxaliplatin resistance seems to follow a different mechanism of action, showing only partial or no cross-resistance to Cis- and
Carboplatin.
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are reported after Cisplatin emerged as first line che-
motherapeutic principle [12]. This is owed to the fact that
testicular cancers do not develop Cisplatin resistance or
cellular defense strategies against the drug. Chemotherapy
is a central constituent for the treatment of cancer
patients. However, cancer cells have the propensity to
become resistant to therapy, which is the major limitation
of current therapeutic concepts. Cancer patients usually
are treated by repeated cycles of chemotherapy and the
clinical course of most cancers is entailed with relapsed
disease in the medium term. These recurrencies are paral-
leled by the development of therapy-refractory tumours
representing a major problem in the clinical management
of cancer patients. The emergence of chemoresistance is a
time-dependent cellular process, which requires concerted
action of many cellular components. Several mechanisms
and pathways are involved in the emergence of a chemore-
sistant phenotype. Among others, general mechanisms of
resistance known today are
￿ diminished drug accumulation
￿ elevated drug inactivation
￿ DNA repair or elevated DNA damage tolerance
￿ enhanced expression of anti-apoptotic genes, and
￿ inactivation of the p53 pathway (all reviewed in
[4]).
However, this knowledge has not yet led to resounding
clinical strategies to overcome cellular resistance: mechan-
isms of resistance are multiple and not all of them are
fully understood. Specific principles of Cisplatin-resistance
are reduced uptake or increased efflux of platinum com-
pounds via heavy metal transporters, cellular comparti-
mentation, detoxification of bioactive platinum aquo-
complexes by Sulphur-containing peptides or proteins,
increased DNA repair, and alterations in apoptotic signal-
ing pathways (reviewed in [5]). Cisplatin and Carboplatin
resistant cells are cross-resistant in all yet known cases. In
contrast, Oxaliplatin resistant tumours often are not cross-
resistant, pointing to a different mechanism of action.
Cisplatin resistance occurs intrinsic (i.e. colon carcinomas
[13]) or acquired (i.e. ovarian carcinomas [14]), but some
tumour specimens show no tendency to aquire resistance
at all (i.e. testicular cancer [12]). Reduced accumulation of
Platinum compounds in the cytosol can be caused by
reduced uptake, increased efflux, or cellular compartimen-
tation. Several ATP binding cassette (ABC) transport pro-
teins are involved like MRP2 and MRP6, Ctr1 and Ctr2,
and ATP7A and ATP7B, respectively [15,16]. However,
the degree of reduced intracellular Cisplatin accumulation
often is not directly proportional to the observed level of
resistance. This may be owed to the fact that usually
several mechanisms of Cisplatin resistance emerge
simultaneously. Another mechanism of resistance is
acquired imbalance of apoptotic pathways. With respect
to drug targets, chemoresistance can also be triggered by
overexpression of receptor tyrosine kinases: ERB B1-4,
IGF-1R, VEGFR 1-3, and PDGF receptor family members
(reviewed in [17,18]). ERB B2 (also called HER 2) for
instance activates the small G protein RAS leading to
downstream signaling of MAPK and proliferation as well
as PI3K/AKT pathway and cell survival. Experiments with
recombinant expression of ERB B2 confirmed this
mechanism of resistance. Meanwhile, numerous research-
ers are focussed on finding new strategies to overcome
chemoresistance and thousands of publications are
availible.
Another very recently discovered mechanism of cispla-
tin resistance is differential expression of microRNA.
RNA interference (RNAi) is initiated by double-stranded
RNA fragments (dsRNA). These dsRNAs are furtheron
catalytically cut into short peaces with a length of 21-28
nucleotides. Gene silencing is then performed by binding
their complementary single stranded RNA, i.e. messenger
RNA (mRNA), thereby inhibiting the mRNAs translation
into functional proteins. MicroRNAs are endogenously
processed short RNA fragments, which are expressed in
order to modify the expression level of certain genes [19].
This mechanism of silencing genes might have tremen-
dous impact on resistance research. A very recently pub-
lished article for instance focussed on differential
microRNA expression in three cisplatin resistant germ
cell tumour cell lines compared to their non-resistant,
cisplatin sensitive counterparts [20]. The authors found a
significant increase in the expression of a microRNA
cluster (hsa-miR-371-373) in the cisplatin resistant situa-
tion, which triggeres p53 silencing [21]. Thus, a future
perspective in the field of cisplatin resistance research
might be to investigate microRNAs.
Thiol-containing proteins and Cisplatin resistance
Among various mechanisms of platinum resistance,
thiol-containing proteins are of special interest. Plati-
num-based complexes are the only heavy metal contain-
ing EMA- and FDA-approved cytostatics at present. This
leads to a very uncommon possible mechanism of resis-
tance: direct interaction of Cisplatin with thiol-groups
forming a virtually insoluble sulphide. Since, this
mechanism of action in resistance formation is exclusive
to platinum-based compounds, it is referred to in this
article with a special chapter.
Glutathione or metallothioneins are cysteine-rich pep-
tides, capable of detoxicating the highly reactive aquo-
complexes. Cisplatin resistance in ovarian cancer was
reported directly proportional to increased intracellular
glutathione [22]. However, increased glutathione levels are
reversible but resistance is not. Upstream of gluthatione
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Mammalian thioredoxins are a family of 10-12 kDa
proteins characterized by a common active site: Trp-Cys-
Gly-Pro-Cys. Thioredoxin-1 (TRX) is a 12 kDA ubiquitous
protein of 104 amino acids with disulfide reducing activity
[23]. TRX is frequently found in the cytoplasm, but was
also identified in the nucleus of benign endometrial stro-
mal cells, tumour derived cell lines, and primary tumours
[24]. Its active site comprises two cystein residues in the
consensus sequence serving as a general disulfide oxido-
reductase. These two cystein residues (Cys-32, Cys-35)
can reversably be oxidized to form a disulfide bond and be
reduced by TRX reductase and NADPH [25]. The TRX
system comprises TRX reductase, NADPH, and TRX
itself. It is conserved throughout evolution from procar-
yotes to higher eucaryotes. The TRX system and the glu-
tathione system constitute important thiol reducing
systems [26]. TRX originally was identified as a hydrogen
donor of ribonucleotide reductase in Escherichia coli [27].
Targeted disruption of the TRX gene in Saccharomyces
cervisiae prolonged the cell cycle [28]. The TRX homolo-
g u eg e n eo fDrosophila melanogaster was identified as
pivotal for female meiosis and early embryonic develop-
ment [29]. The reducing nuclear environment, caused by
thioredoxin, is preferable for the DNA binding activity of
v a r i o u st r a n s c r i p t i o nf a c t o r ss u c ha sA P - 1[ 3 0 ] ,N F - B
[31], and the estrogen receptor [32]. AP-1 activation by
TRX also occurs through an indirect mechanism: TRX
reduces Ref-1, which in turn reduces cysteine residues
within the fos and jun subunits of AP-1, thereby promot-
i n gD N Ab i n d i n g[ 3 0 ] .I nt h eN F - B molecule, TRX
reduces Cys-62 of the p50 subunit in the nucleus, thereby
allowing the transcription factor to bind DNA [33]. TRX
in general regulates protein-nucleic acid interactions
through the redox regulation of cystein residues [34]. In
addition, cellular redox status is pivotal to regulation of
apoptosis. TRX has been shown to bind and inactivate
apoptosis signal-regulating kinase 1 (ASK1), with the latter
to be released upon oxidative stress [35]. Apart from its
cellular functions, TRX can be secreted as an autocrine
growth factor by a yet unknown mechanism. It is then sti-
mulating the proliferation of cells derived from a variety of
solid tumors [36]. In addition, the cytochrom P450 sub-
type 1B1 (CYP1B1) converts 17b-estradiol (abbreviated as
E2) into the carcinogenic 4-hydroxyestradiol (4-OHE2). A
study conducted in ER-positive MCF-7 breast cancer cells
suggested TRX to be involved in the constitutive expres-
sion of CYP1B1 and the dioxin mediated induction of
CYP1B1 [37]. It may, thus, be a potent co-factor of mam-
mary carcinogenesis at least in estradiol responsive
tumours. Like other thiol-containing proteins, thioredoxin
overexpression was suspected triggering chemotherapy
resistance [24]. Hence, TRX overexpression in several
tumour derived cell lines is associated with resistance to
Cisplatin [38]. However, TRX effects on anti-cancer drug
resistance are complex and depend strictly on the tissue
type. For instance, hepatocellular carcinoma cells with ele-
vated thioredoxin levels are resistant to Cisplatin, but not
to the antracyclin Doxorubicin [39]. However, bladder-
and prostate cancer cell lines with TRX overexpression are
Cisplatin resistant and cross-resistant to Doxorubicin [40].
Cisplatin resistance in ovarian cancer cell lines is asso-
ciated with high TRX levels, but recombinant TRX over-
expression in non-resistant cells does not confer resistance
to Cisplatin or Doxorubicin [41]. Thus, Cisplatin-respon-
siveness of a given tumour entity overexpressing TRX is
unpredictable at present.
Breast cancer
For midaged women in the industrialized countries,
breast cancer is the second most common cause of can-
cer-death [10]. Carcinomas of the mammary gland com-
prise rather different diseases referring to divergent cell
types found in the female breast. Breast cancers are
divided into ductal, medullary, lobar, papillary, tubular,
apocrine and adeno-carcinomas, respectively [42]. Breast
cancer is not a purely gynecological disorder: approxi-
mately 1% of breast cancer cases are male patients. Apart
from histological classification, breast cancers are bio-
chemically categorized independent of the tissue origin
with respect to their receptor status:
1. HER-2 positive tumours
2. triple-negative breast cancer (TNBC), which are
ER, PR, and HER-2 negative
3. endocrine-responsive tumours
HER-2 positive tumours are characterized by constitu-
tive overexpression of the HER-2 receptor subtype of the
epidermal growth factor receptor family. Constitutive
overexpression of HER-2 in invasive ductal carcinomas
was reported in about 30% of all cases. On the one hand,
HER-2 overexpression is a negative prognostic marker,
on the other hand, HER-2 positive breast cancer can be
targeted specifically, yielding an improved prognosis and
fewer side effects [43]. No endogenous ligand for this
receptor is known, but HER-2 has a fixed conformation
that resembles the ligand activated state of the other
HER subtypes [44]. In addition, HER-2 is the favoured
dimerization partner of other ERBB receptors. HER-2
can be specifically targeted by means of humanized
monoclonal antibodies Trastuzumab and Pertuzumab,
respectively [18]. Both antibodies can also be adminis-
tered over extended periods of time to avoid breast can-
cer relapse.
Triple negative breast cancer is not amenable to speci-
fically targeted therapies, such as anti-hormone therapy
or Trastuzumab. Therefore, classical chemotherapy is
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tarium at present [45]. In line with this, triple negative
tumours carry a poor prognosis. TNBC accounts for
approximately 15% of all breast cancer cases and
younger (< 50 years) women are more frequently
affected by TNBC than by HER-2 positive or hormone
responsive tumours. It was recently discovered that the
p53 family member p73 triggeres a pathway responsible
for Cisplatin sensitivity in this subset of breast cancer
specimens [46]. Thus, the authors suggested that these
tumours could prevalently be treated with Cisplatin if
stained positive for p73.
I ti ss u g g e s t e dt h a tT N B Co r i g i n sf r o mB R C A 1o r
BRCA2 mutation carriers, since there is a 90% overlap
between TNBC and BRCA mutation. Meanwhile, it is
unveiled that BRCA mutations are often but not always
associated with a triple negative phenotype [47]. However,
especially BRCA mutated genotypes exhibit a Doxorubi-
cine-sensitive [48] and Cisplatin-sensitive phenotype [49].
The reason is that DNA-damage affecting one allel cannot
be compensated by homologous recombination because
this would require an intact BRCA gene [50]. The impaired
ability of homologous recombination is currently investi-
gated in order to develop targeted therapy of BRCA muta-
tion carriers. In BRCA mutated breast cancer patients,
DNA-repair instead of homologous recombination is per-
formed by Base Excision Repair (BER). In this context, a
damaged nucleotide is excised and substituted by an intact
nucleotide. This process requires (among others) the
enzyme Polyadenosine 5’-Diphosphoribose Polymerase
(PARP1). If PARP1 is inhibited in BRCA-mutated cells,
both possibilities of DNA-repair are blocked [51]. This
concept was tested recently with success in therapy-refrac-
tory Tumours with BRCA mutations. In this study, the oral
bioavailable PARP1-inhibitor Olaparib (AZD2281) was
applied. Treatment with Olaparib in a dose-escalation
study caused stabe disease in 63% of cases [52]. Cisplatin as
a directly DNA-interacting substance could be a drug of
choice in combination therapy with Olaparib or any other
PARP1-Inhibitor in BRCA-mutated breast cancer. Thus,
PARP-inhibitors in the future could serve as chemo-senzi-
tisers, which also was already successfully tested in vitro
and in vivo [53,54].
The highest incidences have breast cancer specimens
expressing the estrogen receptor, so-called hormone-
responsive tumours. ER positive tumours are treated either
with cytotoxic drugs, anti-estrogens or a combination of
both. Anti-estrogens are estrogen receptor antagonists like
Tamoxifen, Toremifen, Raloxifen or aromatase inhibitors
blocking chemical transformation of Testosterone to the
aromatic ring-A steroide Estradiol like Letrozole, Anastro-
zole. Since, pharmacologic inhibition is an additional treat-
ment option in these cancer specimens ER expressing
breast carcinomas carry a better prognosis than triple
negative breast carcinomas. In line with this, the primary
therapy approach usually shows good response. However,
patients often face one or more relapses. The etiopathol-
ogy of breast carcinomas often takes years, finally resulting
in chemoresistant tumours. Chemotherapy triplets like
FEC (comprising Fluorouracil, Epirubicin, and Cyclopho-
sphamide) or CMF (Cyclophosphamide, Metothrexate,
and Fluorouracil) are administered with the attempt to
target multiple mechanisms of cancer cell mitosis and to
avoid the emergence of resistance. However, after years or
repeated chemotherapy cycles, the cancer cell finally
aquires multiple resistancies [55]. Some of the applied sub-
stances (for instance Epirubicin) are outwardly transported
by the membrane-spanning transport protein plasmalem-
mal-glycoprotein, 170 kDa P-gp (reviewed in [56]). Since,
platinum-based compounds have no affinity towards P-gp,
platinum based chemotherapy emerged in the recent years
as second line treatment regimen for advanced breast
cancer.
ER-positive breast cancers are the most prevalent form
of the disease. Breast cancer patients with extensive lymph
node involvement (advanced breast cancer) have a high
disease recurrence rate. Eventually, in most women, meta-
static breast cancer becomes refractory to hormonal treat-
ment and chemotherapy [57]. These findings demonstrate
that the development of resistance to therapy is a long
term clinical process. During our studies we have gener-
ated Cisplatin resistant ER-positive breast cancer cells
(MCF-7 CisR) by sequential cycles of Cisplatin exposure
over a period of 6 months. During the first two months
the cells received weekly cycles of Cisplatin followed by
monthly cycles of Cisplatin exposure. We used these cells
to investigate systematically the activities of various signal-
ling networks, comprising ERBB and MAPK signaling
pathways using phospho-proteome profiling. In MCF-7
CisR cells the EGFR is phosphorylated. Downstream we
found Both, MAPK and PI3K/AKT kinase activation with
AKT kinase being reported to mediate chemoresistance in
breast cancer cells. In line with this, inhibition of AKT-
kinase activation by pharmacological tools in MCF-7 CisR
cells was entailed with reversal of Cisplatin resistance. In
addition, AKT kinase up-regulates Bcl-2 expression with
BCL-2 preventing apoptosis independent of the structure
of the causing drug [58].
The EGFR pathway is activated by an array of ligands
binding the four EGFR receptor monomers in divergent
composition [18]. These ligands can act in form of an
autocrine loop in self-sufficient cancer cells. In our study,
gene expression profiling and RT-PCR revealed that
EGFR-ligand amphiregulin is overexpressed and secreted
in resistant MCF-7 cells. Amphiregulin is an exclusive
ligand of the EGFR which induces tyrosine trans-phos-
phorylation of EGFR-dimerized subunits leading to subse-
quent receptor activation [59]. Amphiregulin originally
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treated with the tumour promoter PMA [60]. Amphiregu-
lin increases invasion capabilities of MCF-7 breast cancer
cells, and transcriptional profiling experiments revealed
that amphiregulin promotes distinct patterns of gene
expression compared to EGF [61]. Several genes involved
in cell motility and invasion are upregulated when nontu-
mourigenic breast epithelial cells are cultivated in the pre-
sence of amphiregulin. The cytoplasmic tail of the EGFR
plays a critical role in amphiregulin mitogenic signaling
but is dispensable for EGF signaling [62]. Autocrine loop
formation leading to independence of extrinsic prolifera-
tive signals is a key event in the evolution of malignant
tumours. In our study, we found a significantly increased
ability to invade and penetrate the basement of the matri-
gel invasion assay. These results are in line with published
data and they show that drug resistance and tumour
aggressiveness are interconnected processes. As a proof of
principle, this consideration was tested by amphiregulin
knock down experiments. It was possible to overcome Cis-
platin resistance to a large part by siRNA mediated knock-
down of amphiregulin gene expression. Amphiregulin
protein is anchored to the cell membrane as a 50-kDa
proamphiregulin precursor and is preferentially cleaved by
ADAM 17 at distal site within the ectodomain to release a
major 43-kDa amphiregulin form into the medium [63].
We conclude that MCF-7 cells show persistant alterations
of signaling activity in the ERBB pathway associated with
an inactivation of p53 and BCL-2 overexpression.
An overview of the biochemical mechanisms underly-
ing Cisplatin resistance in MCF-7 breast cancer cells is
given in Figure 2. Once a molecular mechanism is
unveiled it is mandatory to explore whether this finding
is a general mechanism. To address this issue we corre-
lated amphiregulin expression levels with the Cisplatin
resistant state of a collection of human breast cancer
cells and found a correlation which demonstrates that
breast cancer cells use amphiregulin as a survival signal
to resist exposure to Cisplatin [64]. We also analyzed a
collection of lung cancer cells which tend to express ele-
vated levels of amphiregulin, too. In contrast to breast
cancer cells, a correlation between Cisplatin resistance
and amphiregulin expression in lung cancer cells was
not detected. Thus, it is necessary to investigate differ-
ent tumour types and stages in order to determine the
role of amphiregulin for Cisplatin resistance. Further
studies will determine the impact of amphiregulin
expression for therapy response and outcome in women
with breast cancer.
Ovarian cancer
Clinicians have designated ovarian cancer a “silent killer”
because, when diagnosed, the disease usually has already
spread into the peritoneum [65]. If the cancer is diagnosed
while confined to the ovary (localized stage), the 5-year
survival rate is over 90%. In contrast, if ovarian cancer is
diagnosed after it has metastasized (distant stage), the 5-
year survival rate is below 30%. Unfortunately, most cases
( 6 8 % )a r ed i a g n o s e da tt h ed i s t a n ts t a g e .T h u s ,o v a r i a n
cancer has a substantially shorter and more dramatic etio-
pathology than breast cancer: ovarian cancer is the most
lethal gynecological cancer in the industrialized nations
although its first occurrence has a satisfactory clinical
response to platinum-based chemotherapy [10]. The rea-
s o ni st h a tm o r et h a n8 0 %o ft h ep a t i e n t se x p e r i e n c ea n
early relapse [66]. The tumour usually reappears in
advanced stage or as metastatic form of the disease (FIGO
III/IV), which is treated in first line with cytoreductive sur-
gery followed by chemotherapy doublets consisting of a
Platinum-based compound combined with a Taxane.
Resistance to Platinum-containing compounds is a major
obstacle in ovarian cancer therapy and the underlying
mechanisms are not completely understood. Formation of
a Cisplatin resistant phenotype after initial drug response
usually is entailed with a lethal course of the disease after
a relapse [67]. Cellular defense to Cisplatin evolves as con-
certed action of growth factors, RTKs, MAPKs and other
signal transduction pathways. The emergence of ovarian
cancer proceeds with clinically diffuse symptoms [68].
Unfortunately, ovarian cancer is not contemporarily diag-
nosed because early symptoms like abdominal pain are
not regarded as signs of a deadly disease by the patient.
When symptoms aggravate, the patient often is already
moribund. Ovarian cancer incidence peaks in the sixth
and seventh life decade [67]. Approximately 5% of ovarian
cancer cases have a hereditary background: women bear
an increased risk of ovarian cancer if a first-degree relative
suffers from (or died of) ovarian or breast cancer [69].
Therapeutic intervention of ovarian carcinomas can
have different intentions, first, a curative approach
intending the complete removal of the tumour and sig-
nificant extension of survival time. To achieve this objec-
tive, severe side effects are accepted. Second, palliative
therapy intends to enhance patient’s quality of life and to
alleviate pain and other disease symptoms. In the latter
case, aggressive treatment options are avoided. Regarding
chemotherapy, adjuvant and neo-adjuvant regimens are
used: in an adjuvant chemotherapy regimen, cytostatic
drugs are given after a debulking surgery, whereas in a
neo-adjuvant setting, cytostatic drugs are given prior to
cytoreductive surgery. The intention of adjuvant che-
motherapy is to eliminate remaining tumour cells,
thereby, preventing a relapse. Neo-adjuvant chemother-
apy aims at reducing the tumour burden before surgery,
intending to remove the tumour completely with one
large surgery [70].
The crucial step in ovarian carcinoma treatment is the
first surgery of the primary tumour, since only this can
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apy (at present) are only of palliative value. The current
standard chemotherapy comprises a combination of
Carboplatin and Paclitaxel. Alternatively, a combination
of Carboplatin and Gemcitabine may be used. However,
the majority of patients will face relapsed disease.
Approximately 20% are Platinum-refractory early
relapses with very poor prognosis occuring within the
first 6 months after therapy. The remaining 80% are Pla-
tinum-sensitive late relapses. In the first case, Topotecan
or the antracycline Doxorubicin, masked in liposomes of
polyethylenglycol, are considered as a remaining therapy
option. In the latter case (Platinum-sensitive relapse) a
Carboplatin/Paclitaxel doublet remains first choice che-
motherapy. Therapy of relapsed ovarian cancer always is
of palliative nature, thus, intending to delay disease pro-
gression, reduce pain, and maintain quality of life [67].
Clinical findings show that the development of resis-
tance to therapy of ovarian cancer is a time-dependent
biological process [65]. In our study we used A2780
epithelial ovarian cancer cells as a model system to inves-
tigate the molecular determinants of Cisplatin resistance
and uncovered the molecular mechanism of action. Since
A2780 is not a representative cell line for the most com-
mon histology subtype of epithelial ovarian cancer, we
generalized our findings by analysing also HEY, OVCAR-
8, SKOV-3, and BG-1 cell lines. In addition, a clinical
trial with 80 ovarian cancer tumour samples was
analysed. To mimic the clinical situation of Cisplatin
therapy in vitro, we followed the same procedure as with
MCF-7 breast cancer cells: we generated Cisplatin-resis-
tant cells by weekly cycles of Cisplatin at a dose, which is
reached in patients in the clinic and assessed the emer-
gence of resistance during 6 months. We found a correla-
tion of increasing IGF-1R mRNA expression levels with
the emergence of resistance to Cisplatin. In order to ana-
lyse generalisability of this finding, we correlated IGF-1R
mRNA expression with the intrinsic Cisplatin resistance
status in a panel of human ovarian cancer cells and
found a significant correlation [72]. The IGF-1 receptor
is physiologically expressed in the ovary and it was
reported that its pathway is functional in human ovarian
surface epithelial cells which are the origin of most
epithelial ovarian carcinomas [73,74]. It is, therefore, not
surprising that nearly all ovarian carcinomas and ovarian
cancer-derived cell lines express the IGF-1 receptor at
the cell surface [75]. The IGF-1 receptor pathway regu-
l a t e sm a n yp r o c e s s e si no v a r i an epithelial cells [76].
Hyperactivation in our model system is explained by an
IGF-1 based autocrine loop. IGF-1 is a multifunctional
peptide of 70 amino acids. Upon binding to the IGF-1R
the ligand activates the IGF-1R tyrosine kinase function.
After mutual phosphorylation of the b-subunits (Y 950, Y
1131, Y 1135, Y 1136), the active receptor phosphorylates
the adaptor protein insulin receptor substrate (IRS-1) at
S 312. This leads to either complex formation with a
Figure 2 Schematic model of Amphiregulin signalling. Amphiregulin induced signaling of the EGFR/ERBB2 receptor tyrosine kinases in
Cisplatin resistant MCF-7 cells.
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nine nucleotide exchange factor SOS resulting in RAS/
RAF/MEK/ERK activation, or direct activation of PI3
kinase [77]. Class I PI3Ks are divided into two subfami-
lies, depending on the receptors to which they couple.
Class IA PI3Ks are activated by RTKs, whereas class IB
PI3Ks are activated by G-protein-coupled receptors [78].
Class IA PI3Ks are heterodimers of a p85 regulatory sub-
unit and a p110 catalytic subunit. Class IA PI3Ks regulate
growth and proliferation downstream of growth factor
receptors. It is, thereby, interesting to note that the IGF-1
receptor primarily regulates growth and development and
has only a minor function in metabolism [79].
A recent report has shown that coactivation of several
RTKs in glioblastoma obviates the use of single agents
for targeted therapies [80]. Fortunately, in our model
system of Cisplatin resistant ovarian cancer, we did not
detect coactivation of other RTKs besides IGF-1R. To
further analyse this, we functionally inactivated IGF-1 in
tissue culture supernatants which caused a reversion of
the Cisplatin-resistant phenotype. Likewise, inhibition of
IGF-1R transphosphorylation and signaling by small
molecule inhibitors had a similar effect.
We and many other researchers have demonstrated
that signaling through PI3K pathway provokes Cisplatin
resistance in ovarian cancer. In addition, reports from
the literature show that PI3K signaling is important for
the etiology of ovarian cancer. It is well established that
AKT signaling plays a major role for cell survival
(reviewed in [81]). However, AKT isoforms can have dif-
ferent functions as it was shown that AKT1 is required
for proliferation, while AKT2 promotes cell cycle exit
through p21 binding [82]. The AKT2 gene is overex-
pressed in about 12% of ovarian cancer specimens,
which indicates that it may be linked to the etiology of
the disease [83]. However, AKT2 has also been linked to
the maintenance of a Cisplatin resistant phenotype of
ovarian carcinomas: it was shown that AKT2 inhibition
re-sensitized Cisplatin resistant ovarian cancer cells [84].
In our study, an expression profiling from 80 ovarian
carcinomas unveiled the regulatory subunit PIK3R2 as a
negative prognosis factor for ovarian cancer. This result
is in line with the findings of an independent study by
Dressman and coworkers [85].
Common features of Cisplatin resistance models
Table 1 summarizes the key findings of our studies in
gynaecological cancer in vitro models of Cisplatin
resistance.
It is evident that both models exhibit elevated inva-
siveness and specific growth factor receptor activation
exclusively in the Cisplatin resistant situation (red
labeled in table 1). However, the activated class of RTKs
differs in the tumor entities. Cisplatin resistant
(i) breast cancer cells show EGFR/ERBB2 activation
(ii) ovarian cancer cells show IGF-1R activation
At first sight, these tumour entities seem to follow dif-
ferent biochemical mechanisms to archieve a similar func-
tional outcome, which is downstream activation of the
PI3K/AKT-pathway. However, these biochemical signaling
routes converge at a single axis: the estradiol/estrogen
receptor activation, which is the decisive route in female
organ ontogenesis. With respect to developmental pro-
cesses of the respective tissue, the activated receptors in
the Cisplatin resistant state are of high ontogenic impor-
tance. Ontogenesis of the female primary and secondary
sexual organs are divided into two phases with an inter-
mediate quiescence period of 10-15 years: (i) prenatal
organ development and (ii) puberty, resulting in a func-
tioning reproductive system at the time of menarche.
Table 1 Comparison of Cisplatin resistance in vitro models of A2780 ovarian cancer cells and MCF-7 breast-cancer cells
altered in Cisplatin resistant
Read-out MCF-7 CisR A2780 CisR
Cisplatin resistance factor 3.3*** 5.8***
proliferation rate [%] 192** 55.3***
invasive capacity [%] compared to parental cells 153.7* 129.5*
RTK activation in Cisplatin resistant cells EGFR/ERB-B2 IGF-1R
autocrine growth factor amphiregulin IGF-1
bystander effect no IGF-1 mediated
ERK1,2 activation elevated elevated
p38 activation no p38a
JNK activation no no
AKT kinase activation elevated elevated
An overview of the long-term functional and biochemical changes after establishment of Cisplatin resistance is given. Cisplatin resistant breast cancer cells and
ovarian cancer cells were compared to their non-resistant parental cells. Denoted are the changes observed in the Cisplatin resistant situation [64,72].
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At first sight it seems a paradoxon that a mechanism indu-
cing proliferation (amphiregulin) triggeres Cisplatin resis-
tance. A fast growing cell presents a better target for
classical chemotherapeutic drugs. However, both differen-
tially activated RTKs, ERGF and IGF-1R, not only signal
through the MEK/ERK pathway, resulting in enhanced
proliferation responses, but also through the PI3K/AKT
survival pathway. Many of the signaling molecules down-
stream of the receptors are identified as oncogenes, like
ras- or raf small G proteins. Therefore, these factors can
be looked at as a two-edged sword: with the eyes of a
developmental biologist they are pivotal in ontogenesis;
with the eyes of a tumour biologist, they can trigger onco-
genic transformation and concomitantly resistance to che-
motherapy. Since, the PI3K/AKT pathway is a general
apoptosis preventing pathway, resistance is triggered not
only to a special group of drugs but towards chemotherapy
as a whole. This is supported by the finding that the Cis-
platin-resistance models in our studies showed cross-resis-
tance towards Doxorubicine, an anti-cancer drug, which is
chemically unrelated to Cisplatin. Therefore, resistance-
mediating factors derived from proteins with prominent
function in organ ontogenesis could be designated as
“resistogenic”.
Acknowledgements
Critically reviewing of the manuscript by Dr. Bodo Haas
is greatfully acknowledged. This review article was sup-
ported by intramural funding of the Federal Institute for
Drugs and Medical Devices.
List of abbreviations used
RTK: receptor tyrosine kinase; TKI: tyrosine kinase inhibitor; EGFR: epidermal
growth factor receptor; HER-2: Human epidermal growth factor receptor
type 2; IGF-1R: insulin-like growth factor receptor: PDGFR: platelet derived
growth factor receptor; bbb: blood brain barrier; P-gp: P-glycoprotein; TRX:
thioredoxin; MAPK: Mitogen-activated protein kinase; CDK: cyclin-dependent
kinase; ER: estrogen receptor; PR: progesterone receptor; TNBC: triple
negative breast cancer; P-gp: plasmalemmal-glycoprotein; PMA: Phorbol-
Myristate-Acetate; ADAM: a disintegrine and metalloproteinase; IRS-1: Insuline
receptor substrate;
Authors’ contributions
not applicable
Competing interests
The authors declare that they have no competing interests.
Received: 20 July 2011 Accepted: 4 October 2011
Published: 4 October 2011
References
1. Metzger-Filho O, Moulin C, D’Hondt V: First-line systemic treatment of
ovarian cancer: a critical review of available evidence and expectations
for future directions. Curr Opin Oncol 2010, 22:513-20.
2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y,
Pietenpol JA: Identification of human triple-negative breast cancer
subtypes and preclinical models for selection of targeted therapies. J
Clin Invest 2011, 121:2750-67.
3. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N,
Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ,
Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F,
Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A
collection of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell 2006, 10:515-27.
4. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs.
Nature Reviews Drug Discovery 2005, 4:307-20.
5. Stewart DJ: Mechanisms of resistance to cisplatin and carboplatin. Crit
Rev Oncol Hematol 2007, 63:12-31.
6. Broker LE, Kruyt FA, Giaccone G: Cell death independent of caspases: a
review. Clin Cancer Res 2005, 11:3155-62.
7. Ashkenazi A, Herbst RS: To kill a tumor cell: the potential of proapoptotic
receptor agonists. J Clin Invest 2008, 118:1979-90.
8. Fulda S, Debatin KM: Extrinsic versus intrinsic apoptosis pathways in
anticancer chemotherapy. Oncogene 2006, 25:4798-811.
9. Vousden KH, Lu X: Live or let die: the cell’s response to p53. Nat Rev
Cancer 2002, 2:594-604.
10. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: The impact
of eliminating socioeconomic and racial disparities on premature cancer
deaths. CA Cancer J Clin 2011, 61:212-36.
11. Pectasides D, Pectasides E, Kassanos D: Germ cell tumors of the ovary.
Cancer Treat Rev 2008, 34:427-41.
12. Einhorn LH: Curing metastatic testicular cancer. Proc Natl Acad Sci USA
2002, 99:4592-5.
13. Scanlon KJ, Kashani-Sabet M, Sowers LC: Overexpression of DNA
replication and repair enzymes in cisplatin-resistant human colon
carcinoma HCT8 cells and circumvention by azidothymidine. Cancer
Commun 1989, 1:269-75.
14. Scanlon KJ, Lu Y, Kashani-Sabet M, Ma J, Newman E: Mechanisms for
cisplatin-FUra synergism and cisplatin resistance in human ovarian
carcinoma cells both in vitro and in vivo. Adv Exp Med Biol 1988,
244:127-35.
15. Konkimalla VB, Kaina B, Efferth T: Role of transporter genes in cisplatin
resistance. Vivo 2008, 22:279-83.
16. Ishida S, Lee J, Thiele DJ, Herskowitz I: Uptake of the anticancer drug
cisplatin mediated by the copper transporter Ctr1 in yeast and
mammals. Proc Natl Acad Sci USA 2002, 99:14298-302.
17. Koberle B, Tomicic MT, Usanova S, Kaina B: Cisplatin resistance: preclinical
findings and clinical implications. Biochim Biophys Acta 2010, 1806:172-82.
18. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of
targeted inhibitors. Nat Rev Cancer 2005, 5:341-54.
19. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded
RNA. Nature 2004, 431:343-9.
20. Port M, Glaesener S, Ruf C, Riecke A, Bokemeyer C, Meineke V, Honecker F,
Abend M: Micro-RNA expression in cisplatin resistant germ cell tumor
cell lines. Mol Cancer 2011 10:52.
21. Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW, Sun Y, Chen C, Guenther S,
Sherlock J, Veltman I, Baeten J, van der Spek PJ, de AP, Looijenga LH: High-
throughput microRNAome analysis in human germ cell tumours. J Pathol
2007, 213:319-28.
22. Lukyanova NY: Characteristics of homocysteine-induced multidrug
resistance of human MCF-7 breast cancer cells and human A2780
ovarian cancer cells. Exp Oncol 2010, 32:10-4.
23. Holmgren A: Thioredoxin structure and mechanism: conformational
changes on oxidation of the active-site sulfhydryls to a disulfide.
Structure 1995, 3:239-43.
24. Powis G, Montfort WR: Properties and biological activities of thioredoxins.
Annu Rev Biophys Biomol Struct 2001, 30:421-55.
25. Holmgren A: Reduction of disulfides by thioredoxin. Exceptional
reactivity of insulin and suggested functions of thioredoxin in
mechanism of hormone action. J Biol Chem 1979, 254:9113-9.
26. Holmgren A: Thioredoxin and glutaredoxin systems. J Biol Chem 1989,
264:13963-6.
27. Laurent TC, Moore EC, Reichard P: Enzymatic synthesis of
deoxyribonucleotides. iv. isolation and characterization of thioredoxin,
the hydrogen donor from escherichia coli b. J Biol Chem 1964,
239:3436-44.
Eckstein Journal of Experimental & Clinical Cancer Research 2011, 30:91
http://www.jeccr.com/content/30/1/91
Page 9 of 1128. Muller EG: Thioredoxin deficiency in yeast prolongs S phase and
shortens the G1 interval of the cell cycle. J Biol Chem 1991, 266:9194-202.
29. Salz HK, Flickinger TW, Mittendorf E, Pellicena-Palle A, Petschek JP,
Albrecht EB: The Drosophila maternal effect locus deadhead encodes a
thioredoxin homolog required for female meiosis and early embryonic
development. Genetics 1994, 136:1075-86.
30. Abate C, Patel L, Rauscher FJ, Curran T: Redox regulation of fos and jun
DNA-binding activity in vitro. Science 1990, 249:1157-61.
31. Toledano MB, Leonard WJ: Modulation of transcription factor NF-kappa B
binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA
1991, 88:4328-32.
32. Hayashi S, Hajiro-Nakanishi K, Makino Y, Eguchi H, Yodoi J, Tanaka H:
Functional modulation of estrogen receptor by redox state with
reference to thioredoxin as a mediator. Nucleic Acids Res 1997, 25:4035-40.
33. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT: Thioredoxin
regulates the DNA binding activity of NF-kappa B by reduction of a
disulphide bond involving cysteine 62. Nucleic Acids Res 1992, 20:3821-30.
34. Xanthoudakis S, Miao G, Wang F, Pan YC, Curran T: Redox activation of
Fos-Jun DNA binding activity is mediated by a DNA repair enzyme.
EMBO J 1992, 11:3323-35.
35. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M,
Miyazono K, Ichijo H: Mammalian thioredoxin is a direct inhibitor of
apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998, 17:2596-606.
36. Oblong JE, Berggren M, Powis G: Biochemical, structural, and biological
properties of human thioredoxin active site peptides. FEBS Lett 1994,
343:81-4.
37. Husbeck B, Powis G: The redox protein thioredoxin-1 regulates the
constitutive and inducible expression of the estrogen metabolizing
cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells.
Carcinogenesis 2002, 23:1625-30.
38. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y, Takabayashi A,
Spyrou G, Holmgren A, Yodoi J: Possible involvement of thioredoxin
reductase as well as thioredoxin in cellular sensitivity to cis-
diamminedichloroplatinum (II). Free Radic Biol Med 1999, 27:504-14.
39. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, Kohno K,
Takenaka K, Sugimachi K, Kuwano M: Enhanced coexpression of
thioredoxin and high mobility group protein 1 genes in human
hepatocellular carcinoma and the possible association with decreased
sensitivity to cisplatin. Cancer Res 1996, 56:5330-3.
40. Yokomizo A, Ono M, Nanri H, Makino Y, Ohga T, Wada M, Okamoto T,
Yodoi J, Kuwano M, Kohno K: Cellular levels of thioredoxin associated
with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and
etoposide. Cancer Res 1995, 55:4293-6.
41. Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T: Overexpression
of thioredoxin does not confer resistance to cisplatin in transfected
human ovarian and colon cancer cell lines. Cancer Chemother Pharmacol
1997, 40:31-7.
42. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ,
Edwards BK, Berry DA: The decrease in breast-cancer incidence in 2003 in
the United States. N Engl J Med 2007, 356:1670-4.
43. Fischer OM, Streit S, Hart S, Ullrich A: Beyond Herceptin and Gleevec. Curr
Opin Chem Biol 2003, 7:490-5.
44. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO,
Kofler M, Jorissen RN, Nice EC, Burgess AW, Ward CW: The crystal structure
of a truncated ErbB2 ectodomain reveals an active conformation, poised
to interact with other ErbB receptors. Mol Cell 2003, 11:495-505.
45. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L,
Hait W, Toppmeyer D: Locoregional relapse and distant metastasis in
conservatively managed triple negative early-stage breast cancer. J Clin
Oncol 2006, 24:5652-7.
46. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW: The p63/p73
network mediates chemosensitivity to cisplatin in a biologically defined
subset of primary breast cancers. J Clin Invest 2007, 117:1370-80.
47. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO: Histologic
grading is an independent prognostic factor in invasive lobular
carcinoma of the breast. Breast Cancer Res Treat 2008, 111:121-7.
48. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB,
Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den OA,
van GB, Hooning MJ, Brekelmans CT, Klijn JG: Sensitivity to First-Line
Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2
Mutation Carriers. J Clin Oncol 2009.
49. Imyanitov EN: Breast cancer therapy for BRCA1 carriers: moving towards
platinum standard? Hered Cancer Clin Pract 2009, 7:8.
50. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB,
Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP,
Smith GC, Ashworth A: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature 2005, 434:917-21.
51. Lord CJ, Garrett MD, Ashworth A: Targeting the double-strand DNA
break repair pathway as a therapeutic strategy. Clin Cancer Res 2006,
12:4463-8.
52. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P,
Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB,
Schellens JH, de Bono JS: Inhibition of Poly(ADP-Ribose) Polymerase in
Tumors from BRCA Mutation Carriers. N Engl J Med 2009.
53. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S,
Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR,
Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE,
Williams KJ, Curtin NJ: Anticancer chemosensitization and
radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor
AG14361. J Natl Cancer Inst 2004, 96:56-67.
54. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin N,
Boddy A, McHugh P, Newell D, Harris A, Johnson P, Steinfeldt H, Dewji R,
Wang D, Robson L, Calvert H: Phase I study of the poly(ADP-ribose)
polymerase inhibitor, AG014699, in combination with temozolomide in
patients with advanced solid tumors. Clin Cancer Res 2008, 14:7917-23.
55. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R,
Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L,
Slamon D: Randomized phase III study of trastuzumab, paclitaxel, and
carboplatin compared with trastuzumab and paclitaxel in women with
HER-2-overexpressing metastatic breast cancer. Journal of Clinical
Oncology 2006, 24:2786-92.
56. Gottesman MM, Ling V: The molecular basis of multidrug resistance in
cancer: The early years of P-glycoprotein research. Febs Letters 2006,
580:998-1009.
57. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998,
339:974-84.
58. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW: Apoptosis defects
and chemotherapy resistance: molecular interaction maps and networks.
Oncogene 2004, 23:2934-49.
59. Johnson GR, Kannan B, Shoyab M, Stromberg K: Amphiregulin induces
tyrosine phosphorylation of the epidermal growth factor receptor and
p185erbB2. Evidence that amphiregulin acts exclusively through the
epidermal growth factor receptor at the surface of human epithelial cells. J
Biol Chem 1993, 268:2924-31.
60. Shoyab M, McDonald VL, Bradley JG, Todaro GJ, Amphiregulin : a
bifunctional growth-modulating glycoprotein produced by the phorbol
12-myristate 13-acetate-treated human breast adenocarcinoma cell line
MCF-7. Proc Natl Acad Sci USA 1988, 85:6528-32.
61. Willmarth NE, Ethier SP: Autocrine and juxtacrine effects of amphiregulin
on the proliferative, invasive, and migratory properties of normal and
neoplastic human mammary epithelial cells. J Biol Chem 2006,
281:37728-37.
62. Wong L, Deb TB, Thompson SA, Wells A, Johnson GR: A differential
requirement for the COOH-terminal region of the epidermal growth
factor (EGF) receptor in amphiregulin and EGF mitogenic signaling. J Biol
Chem 1999, 274:8900-9.
63. Brown CL, Meise KS, Plowman GD, Coffey RJ, Dempsey PJ: Cell surface
ectodomain cleavage of human amphiregulin precursor is sensitive to a
metalloprotease inhibitor. Release of a predominant N-glycosylated 43-
kDa soluble form. J Biol Chem 1998, 273:17258-68.
64. Eckstein N, Servan K, Girard L, Cai D, von JG, Jaehde U, Kassack MU,
Gazdar AF, Minna JD, Royer HD: Epidermal growth factor receptor
pathway analysis identifies amphiregulin as a key factor for cisplatin
resistance of human breast cancer cells. J Biol Chem 2008, 283:739-50.
65. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ,
Xu X, Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell 2004,
5:19-24.
66. Gotlieb WH, Bruchim I, Ben-Baruch G, Davidson B, Zeltser A, Andersen A,
Olsen H: Doxorubicin levels in the serum and ascites of patients with
ovarian cancer. Eur J Surg Oncol 2007, 33:213-5.
67. Cannistra SA: Cancer of the ovary. N Engl J Med 2004, 351:2519-29.
Eckstein Journal of Experimental & Clinical Cancer Research 2011, 30:91
http://www.jeccr.com/content/30/1/91
Page 10 of 1168. Goff BA, Matthews B, Andrilla CH, Miller JW, Trivers KF, Berry D, Lishner DM,
Baldwin LM: How are symptoms of ovarian cancer managed?: A Study of
Primary Care Physicians. Cancer 2011.
69. Long KC, Kauff ND: Hereditary ovarian cancer: recent molecular insights
and their impact on screening strategies. Curr Opin Oncol 2011.
70. Trope C, Kaern J: Adjuvant chemotherapy for early-stage ovarian cancer:
review of the literature. J Clin Oncol 2007, 25:2909-20.
71. Trope C, Kaern J: Primary surgery for ovarian cancer. Eur J Surg Oncol
2006, 32:844-52.
72. Eckstein N, Servan K, Hildebrandt B, Politz A, von JG, Wolf-Kummeth S,
Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-
Pokora B, Denkert C, Royer HD: Hyperactivation of the insulin-like growth
factor receptor I signaling pathway is an essential event for cisplatin
resistance of ovarian cancer cells. Cancer Res 2009, 69:2996-3003.
73. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface
epithelium: biology, endocrinology, and pathology. Endocr Rev 2001,
22:255-88.
74. Kuroda H, Mandai M, Konishi I, Yura Y, Tsuruta Y, Hamid AA, Nanbu K,
Matsushita K, Mori T: Human chorionic gonadotropin (hCG) inhibits
cisplatin-induced apoptosis in ovarian cancer cells: possible role of up-
regulation of insulin-like growth factor-1 by hCG. Int J Cancer 1998,
76:571-8.
75. Kalli KR, Conover CA: The insulin-like growth factor/insulin system in
epithelial ovarian cancer. Front Biosci 2003, 8:d714-d722.
76. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC: The insulin-related
ovarian regulatory system in health and disease. Endocr Rev 1999,
20:535-82.
77. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and
regulation of Akt/PKB by the rictor-mTOR complex. Science 2005,
307:1098-101.
78. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-
kinases as regulators of growth and metabolism. Nat Rev Genet 2006,
7:606-19.
79. LeRoith D, Werner H, Neuenschwander S, Kalebic T, Helman LJ: The role of
the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci 1995,
766:402-8.
80. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH,
Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L,
DePinho RA: Coactivation of receptor tyrosine kinases affects the
response of tumor cells to targeted therapies. Science 2007, 318:287-90.
81. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell
2007, 129:1261-74.
82. Heron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D,
Hemmings BA, Fernandez A, Lamb NJ: Only Akt1 is required for
proliferation, while Akt2 promotes cell cycle exit through p21 binding.
Mol Cell Biol 2006, 26:8267-80.
83. Bellacosa A, de FD, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M,
Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti PP, Mancuso S,
Neri G, Testa JR: Molecular alterations of the AKT2 oncogene in ovarian
and breast carcinomas. Int J Cancer 1995, 64:280-5.
84. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ: AKT2
inhibition of cisplatin-induced JNK/p38 and Bax activation by
phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol
Chem 2003, 278:23432-40.
85. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J,
Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR,
Lancaster JM: An integrated genomic-based approach to individualized
treatment of patients with advanced-stage ovarian cancer. J Clin Oncol
2007, 25:517-25.
doi:10.1186/1756-9966-30-91
Cite this article as: Eckstein: Platinum resistance in breast and ovarian
cancer cell lines. Journal of Experimental & Clinical Cancer Research 2011
30:91.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Eckstein Journal of Experimental & Clinical Cancer Research 2011, 30:91
http://www.jeccr.com/content/30/1/91
Page 11 of 11